 This was a Phase II, randomized, open-label, rater-blinded, three-arm study comparing two different doses of alemtuzumab LemtradaTM and one dose of subcutaneous SC interferon beta-1a Rebif in participants with early, active relapsing-remitting multiple sclerosis MS who had not been previously treated with MS therapies other than steroids. The study was conducted for an initial period of 3 years and a follow-up to 5 years or more. 